Moderna and Pfizer are testing mRNA flu shots that target the strains most likely to circulate during the 2022 flu season
as being most likely to circulate during the 2022-2023 flu season in the northern hemisphere. The early studies from both Pfizer and Moderna showed the mRNA flu vaccine was safe, which led to the ongoing late-stage studies that will focus more specifically on demonstrating whether the shots are effective at protecting people from influenza. Current vaccines, which use decades-old technology that involves growing the influenza virus in chicken eggs, have traditionally been moderately effective.
mRNA vaccines should eliminate this mismatch. Because the technology is more flexible, manufacturers can create shots with new genetic sequences in about three months or so. That means that if a bad mismatch occurs during a flu season, scientists could potentially produce a new batch of mRNA flu vaccines targeting the right genetic sequences during the same seasonThat, in turn, could reduce the hospitalizations and deaths caused by influenza, which still remain relatively high.
While an mRNA flu shot would be a huge advance in vaccine technology, there may be other ways to protect people from respiratory illness with combination shots. In a separate trial, Moderna is also investigating combination vaccines that would immunize people against both SARS-CoV-2 and influenza in a single shot.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Alpine concept, modern Renault 4 set for 2022 Paris auto showFrench performance marque Alpine is developing 3 EVs, and an upcoming concept will likely preview one.
Consulte Mais informação »
Harris County Public Health Has Pfizer Omicron Booster ShotsThe new COVID-19 vaccination booster shots are now available and Harris County Public Health began giving them out Monday. The bivalent Pfizer COVID-19 booster vaccine authorized for individuals 12 years and older, is available to eligible residents and is administered in a single dose. The new vaccine is designed to protect...
Consulte Mais informação »
Pfizer starts late-stage trial of mRNA-based flu vaccinePfizer Inc said on Wednesday it had started a late-stage U.S. trial of an influenza vaccine involving 25,000 patients, among the first such studies for a messenger RNA flu shot.
Consulte Mais informação »
Pfizer begins late-stage human study on an mRNA flu shotDrugmaker Pfizer said Wednesday it has begun a late-stage human trial of an influenza vaccine that uses the pioneering messenger-RNA deployed widely for the coronavirus.
Consulte Mais informação »
The Most Common Side Effects Of The New Bivalent COVID BoosterHere's what you can expect when you get the Pfizer or Moderna vaccine and how you can ease any symptoms.
Consulte Mais informação »